JERUSALEM--(BUSINESS WIRE)--Marking a major milestone for the company, Oramed Pharmaceuticals Inc. (OTCBB:ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the Israeli Patent Office. The patent, entitled “Methods and Compositions for Oral Administrations of Proteins,” covers a central facet of the company’s core technology. Oramed’s portfolio now consists of two issued patents and 35 patents pending for its technologies and products.
